Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Follow-up study of allogeneic iPS cell-derived cardiomyocyte sheet for dilated cardiomyopathy
jRCT2053250019Active, not recruiting
- Start
- May 2025
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of Human (allogeneic) iPS cell derived-cardiomyocyte sheet in dilated cardiomyopathy (DCM). Primary endpoint: Lifetime follow-up. Started May 2025; status: active, not recruiting.
02
Drugs
Human (allogeneic) iPS cell derived-cardiomyocyte sheet
03
Conditions
dilated cardiomyopathy (DCM)
Beyond the preview
Go deeper on jRCT2053250019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2053250019.